TABLE 1.
Placebo | TXA | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No sample | Blood sample | No sample | Blood sample | |||||||
Variable | n | Median [IQR] or % | n | Median [IQR] or % | P | n | Median [IQR] or % | n | Median [IQR] or % | P |
Age | 39 | 43 [27–60] | 129 | 35 [25–54] | .27 | 38 | 58 [24–69] | 156 | 41 [27–56] | .04 |
Male gender | 27 | 69% | 107 | 83% | .07 | 27 | 71% | 117 | 75% | .68 |
ISS | 39 | 29 [20–34] | 129 | 21 [17–30] | .01 | 37 | 26 [20–31] | 155 | 25 [17–31] | .72 |
Head AIS | 39 | 4 [3–5] | 129 | 4 [3–5] | .13 | 38 | 4 [3–5] | 156 | 4 [3–5] | .72 |
Penetrating injury | 6 | 15% | 8 | 6% | .09 | … | … | … | … | … |
Abbreviations: AIS, Abbreviated Injury Score; IQR, interquartile range; ISS, Injury Severity Score; TXA, tranexamic acid.
No comparison was made for penetrating injury in the TXA group due to a lack of patients in the no-sample population.